1. Scrip
  2. >>Business
  3. >>Deals

How BMS Won A Ten-Day, Three-Way Race To Snap Up RayzeBio

 
• By Alaric DeArment

An SEC filing shows how what started as mostly partnering talks quickly escalated to acquisition discussions, with BMS prevailing over two competing suitors in the end.

Inside BMS's deal to acquire RayzeBio in December • Source: Shutterstock

Bristol Myers Squibb Company looked to speed up its deal to acquire RayzeBio, Inc. as it became clear that two other companies were also in a race to buy it, ultimately leading the drug maker to greatly increase its per-share offering price, a regulatory filing by RayzeBio shows.

The 25 January Securities and Exchange Commission filing goes into detail about how BMS’s deal to acquire the San Diego-based radiopharmaceuticals-focused biotech for $4.1bn, or $62.50 per share, happened. The...

Key Takeaways

  • An SEC filing shows that Bristol Myers Squibb beat out two competing suitors to acquire RayzeBio.

  • The race was on when, on 15 December,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Deal Watch: QurAlis Targets Fragile-X Syndrome In Deals With Quiver, UMass

 
• By Joseph Haas

Plus the end of Sanofi’s six-target alliance with IGM, OmniAb’s deals with Veraxa and Angelini, alliances involving Skye/Arecor, Genprex/UTHealth Houston and more.

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

Genentech, Orionis Stick Together In Second Molecular Glue Deal

 
• By Alaric DeArment

Deal Snapshot: Orionis and Genentech signed a new partnership focused on molecular glues, on top of the one that they struck in 2023.

More from Business

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.

Finance Watch: SV Closes Second Dementia Discovery Fund, Exceeding $250m Goal

 
• By Mandy Jackson

Private Company Edition: SV Health Investors revealed the final closing of its second Dementia Discovery Fund. Also, Eikon cut nearly 15% of its staff, Pathos AI raised $365m in series D venture capital and CellCentric completed a $120m series C round, among other financings.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.